Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. - Archive ouverte HAL Access content directly
Journal Articles World Journal of Surgical Oncology Year : 2013

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

(1) , (2) , (3) , (2) , (3) , (1, 4)
1
2
3
4

Abstract

Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
Fichier principal
Vignette du fichier
1477-7819-11-171.pdf (1.32 Mo) Télécharger le fichier
Vignette du fichier
1477-7819-11-171.xml (30.12 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00850497 , version 1 (06-08-2013)

Identifiers

Cite

Sabrina Kermiche-Rahali, Aude Di Fiore, Fanny Drieux, Frédéric Di Fiore, Arnaud François, et al.. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.. World Journal of Surgical Oncology, 2013, 11 (1), pp.171. ⟨10.1186/1477-7819-11-171⟩. ⟨inserm-00850497⟩
254 View
249 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More